It’s time to talk about biotech and 2021. What will the year ahead look like for biotech and pharma companies and for the investors who finance the drugs they develop?
Adam Koppel, a longtime health care investor and industry executive, joined STAT’s biotech podcast, “The Readout Loud” to try to answer that question. Four years ago, he co-founded Bain Capital Life Sciences, a Boston-based life sciences investment fund with more than $2 billion in assets under management.
A transcript of the interview has been lightly edited for clarity.
Thank you, guys. This is why I subscribe to STAT.